Meropenem
Cystic Fibrosis
University GhentSmall moleculePhase 4 / ApprovedDormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 73/ 100
Competitive context
82 Active assets in the Cystic Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tezacaftor Vertex Pharmaceuticals Incorporated | Phase 4 | A |
Lumacaftor Hospices Civils de Lyon | Phase 4 | BBB |
Liprotamase Anthera Pharmaceuticals | Phase 4 | BBB |
Ivacaftor Meyer Children's Hospital IRCCS | Phase 4 | BBB |
ELEXACAFTOR Meyer Children's Hospital IRCCS | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Meropenem is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →